MetaCap

Alvotech (ALVO) vs Maze Therapeutics (MAZE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Maze Therapeutics (MAZE) has outperformed Alvotech (ALVO) over the past year, losing 13.5% versus a loss of 19.8%. Maze Therapeutics is the larger company by market cap ($1.72 billion vs $1.47 billion), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALVO-19.84%MAZE-13.49%
+47%+1%-46%
Nov 21, 20251 yearNov 20, 2026
ALVO-67.61%MAZE+96.68%
+229%+69%-90%
Jan 27, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALVO versus MAZE key metrics
MetricALVOMAZE
Share price$4.12$31.37
Market cap$1.47B$1.72B
1-day change-3.96%-3.27%
YTD return-19.69%-24.28%
1-year return-19.84%-13.49%
Forward P/E19.46—
EPS (TTM)$-0.82$-2.62
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$586.32M—
Revenue growth (YoY)+19.74%—
Net income (latest FY)$27.92M$-131.12M
Gross margin59.82%—
Operating margin13.34%—
Net margin4.76%—
52-week high$6.53$53.65
52-week low$2.94$21.95
Distance from 52-week high-36.91%-41.53%
Analyst consensusbuystrong_buy
Avg. price target upside+82.04%+99.11%
Average volume1.13M737.14K
Shares outstanding356.82M54.68M
Employees1,279141
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Alvotech

ALVO stock →

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,279 employees

About Maze Therapeutics

MAZE stock →

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees

ALVO vs MAZE FAQ

Which is bigger, Alvotech or Maze Therapeutics?

Maze Therapeutics (MAZE) is larger, with a market capitalization of $1.72B compared with $1.47B for Alvotech (ALVO).

Which stock has performed better over the past year, ALVO or MAZE?

MAZE returned -13.49% over the past 12 months, compared with -19.84% for ALVO (price return, excluding dividends). Past performance does not predict future results.

Are Alvotech and Maze Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons